Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

275 results about "Kinin" patented technology

A kinin is any of various structurally related polypeptides, such as bradykinin and kallidin. They are members of the autacoid family. They act locally to induce vasodilation and contraction of smooth muscle. Kinins function as mediators for inflammatory responses by triggering the immune system. They are also able to regulate cardiovascular and renal function through mediating the effects of ACE inhibitors.

Use of kinin or derivative thereof in treatment of hypertension and prevention or treatment of hypertension complications

PCT designated stage expiredWO2025021146A1Kallidin/bradykinin ingredientsPeptide preparation methodsReceptorKinin
Provided is a long-acting kinin or a derivative thereof, for use in fundamentally solving the problem that the kinin is undruggable. On the one hand, the half-life period of the kinin or the derivative thereof is prolonged by means of long-acting technology, preventing the kinin or the derivative thereof from being rapidly degraded and inactivated in vivo; and on the other hand, action sites of the kinin and a receptor are covered or partially covered by means of long-acting modification, effectively avoiding rapid decrease of blood pressure in a short time, hypotension, and other adverse reactions. The long-acting kinin or the derivative thereof well retains receptor binding activity and signal conduction activity in an in-vitro cell experiment, and can effectively treat hypertension and prevent or treat hypertension complications in in-vivo experiments, and thus a novel method for treating hypertension and hypertension complications is provided.
Owner:ZONHON BIOPHARMA INST

Triple compound acid composition with skin brightening and acne removing effects, product and application of triple compound acid composition

The invention belongs to the technical field of daily chemistry, and provides a triple compound acid composition with skin brightening and acne removing effects, a product and application of the triple compound acid composition and the product, the triple compound acid composition comprises mandelic acid, salicylic acid and succinic acid, and the mass ratio of the mandelic acid to the salicylic acid to the succinic acid is (3-6): (1-2): (1-2). The invention further provides a product containing the composition and application of the product. The composition provided by the invention is synergistically used, has a synergistic effect in the aspect of exfoliating, especially in the aspect of improving the activity of kallikrein 5 (KLK5), not only has the effects of biological skin glowing and exfoliating, but also can efficiently down-regulate the expression of I-type 5alpha-reductase genes, so that the synthesis of sebum is inhibited, and an oil control effect is achieved; in addition, the composition provided by the invention has the effects of brightening, inhibiting bacteria and resisting inflammation, has low sensitization, can be used for removing acnes, takes effect quickly and does not relapse.
Owner:GUANGZHOU JIYAN COSMETICS TECH CO LTD

Monoclonal antibody against human tissue kallikrein 1 and application thereof

The invention discloses an anti-human tissue kallikrein 1 monoclonal antibody and an application thereof. The anti-human tissue kallikrein 1 monoclonal antibody comprises any one of a monoclonal antibody CELL-2, a monoclonal antibody CELL-5 or a monoclonal antibody CELL-6 or a combination of at least two of the monoclonal antibody CELL-2, the monoclonal antibody CELL-5 and the monoclonal antibody CELL-6. The anti-human tissue kallikrein 1 monoclonal antibody provided by the invention is produced by immunizing natural tissue kallikrein, and can effectively recognize tissue kallikrein in human serum / urine.
Owner:JIANGSU AIDEA PHARMACEUTICAL CO LTD +1

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
Owner:TAKEDA PHARMA CO LTD

Compositions and methods for treating allergic inflammatory conditions

Provided are methods for increasing SPINK7 anti-proteinase activity in a target tissue of a subject having an allergic inflammatory condition characterized by inflammation of a squamous epithelium in the target tissue, the method comprising inhibiting kallikrein 5 (KLK5) proteinase activity in the target tissue. Suitable KLK5 inhibitors may include a KLK5-Fc fusion protein, a KLK5 anti-sense polynucleotide, a KLK5-directed miRNA, a KLK5-directed shRNA, a KLK5-directed antibody, or a coumarin compound such as 3-(3-chlorophenyl) carboxy-7-hydroxymethyl coumarin or 3-carboxy-7-hydroxymethyl coumarin.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI

Application of kinin or derivative thereof in treatment of hypertension and prevention or treatment of hypertension complications

PendingCN119584979AKallidin/bradykinin ingredientsPeptide preparation methodsReceptorKinin
The provided long-acting kinin or the derivative thereof fundamentally solves the problem that kinin has no druggability, on one hand, the half-life period of kinin or the derivative thereof is prolonged through a long-acting technology, and it is prevented that kinin or the derivative thereof is rapidly degraded and inactivated in vivo; on the other hand, the action site of the kinin and the receptor is covered or partially covered through long-acting modification, so that the adverse reactions such as rapid blood pressure reduction and hypotension in a short time are effectively avoided. The long-acting kinin or the derivative thereof well retains receptor binding activity and signal transduction activity in an in-vitro cell experiment, can effectively treat hypertension and prevent or treat hypertension complications in an in-vivo experiment, and provides a new method for treating hypertension and hypertension complications.
Owner:ZONHON BIOPHARMA INST

Neurokinin-1 receptor antagonist compounds

The invention discloses a neurokinin-1 receptor antagonist compound, a compound with a structure as shown in a formula (II), a formula (III) or a formula (IV), an isomer, or a pharmaceutically acceptable salt or acid or a deuterated substance thereof, the compound has proper solubility, can be quickly converted into an active metabolite rolapitant in plasma and liver, and can be used for preparing the neurokinin-1 receptor antagonist. The problems that rolapitant is poor in solubility and a conventional injection preparation is difficult to develop are solved, meanwhile, the hemolysis effect can be avoided, and the injection risk is reduced. Compared with an existing prodrug molecule (the compound shown in the formula (I)), the compound has the advantages that the speed of converting and releasing an active metabolite rolapitant in vivo is higher, the in-vivo exposure of the active metabolite rolapitant is higher, and better pharmacokinetic properties are shown. # imgabs0 #
Owner:CREADEV (NANJING) PHARMACEUTICAL TECHNOLOGY CO LTD

Protein biomarkers of inflammatory activity in multiple sclerosis

PendingUS20250189541A1Nervous disorderPeptide/protein ingredientsZymogenUrokinase Plasminogen Activator
The present invention includes a method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising: determining a level of expression for two or more biomarkers selected from urokinase plasminogen activator (uPA), kallikrein-8 (hK8), kallikrein-11 (hK11), or desmoglein-3 (DSG3) in a biological sample of a subject when compared to the same type of sample from a subject or a population of subjects that do not have RRMS; diagnosing that the subject in undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject; and administering a therapeutically effective amount of treatment for RRMS to the subject.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA +1

Plasma kallikrein binding proteins

Plasma kallikrein binding proteins and methods of using such proteins are described.
Owner:TAKEDA PHARMA CO LTD

Polypeptide composition for promoting skin desquamation as well as preparation method and application thereof

The invention discloses a polypeptide composition for promoting skin desquamation and a preparation method and application thereof, the polypeptide composition comprises polypeptides and a polyol preservative, the polypeptides comprise a first polypeptide, a second polypeptide and a third polypeptide, and the first polypeptide is acetyl tetrapeptide-2; the second polypeptide comprises one or more of hyaluronic acid polypeptide, red scorpion toxin and palmitoyl tripeptide-5; and the third polypeptide is prepared from one or more of acetyl octapeptide-3, palmitoyl dipeptide-7, acetyl tetrapeptide-9 and acetyl tetrapeptide-11. The polypeptide composition can significantly up-regulate the gene expression of kallikrein through a synergistic effect and promote old cutin exfoliation; meanwhile, gene expression of metalloproteinase is inhibited, and light aging is delayed. The polypeptide composition disclosed by the invention can be prepared into various cosmetics and has multiple effects of promoting skin desquamation, resisting wrinkles and repairing barriers.
Owner:HANGZHOU PEPTIDE BIOCHEM +1

Curcumin compositions and methods of use as an NK3 antagonist

PendingUS20240408165A1Peptide/protein ingredientsKetone active ingredientsKininHot flashes/flushes
Disclosed herein are compositions for treating, ameliorating, preventing, or reducing the symptoms associated with menopause and / or hot flashes. The compositions disclosed herein comprise a curcumin composition, a green tea extract composition, and a phycocyanin composition that act as neurokinin 3 receptor antagonists. Also described herein are methods utilizing the aforementioned compositions.
Owner:BONAFIDE HEALTH LLC

Assays for determining plasma kallikrein system biomarkers

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
Owner:TAKEDA PHARMA CO LTD

Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.
Owner:TAKEDA PHARMA CO LTD

Plasma kallikrein inhibitor and use thereof

To provide a plasma kallikrein inhibitor and its use.SOLUTION: The present invention provides a compound and a composition thereof, which are useful as a plasma kallikrein inhibitor and exhibit desirable properties as the inhibitor.SELECTED DRAWING: None
Owner:TAKEDA PHARMA CO LTD

Polyethylene glycol-modified form of kinin or derivative thereof and pharmaceutical use thereof

PendingEP4471050A1Senses disorderNervous disorderCerebral paralysisReceptor
The present invention relates to polyethylene glycol-modified form of kinin or derivative thereof and pharmaceutical use thereof. In one aspect, by PEG modification technology, the half-life of the kinin is greatly prolonged, meanwhile, the biological activity of the kinin is exerted, and the problem that pure kinin has extremely short half-life and therefore has no druggability is solved. PEG modifiers used include, but are not limited to, SPA, SCM and SS modifiers, and can be linear or branched PEG modifiers. In another aspect, the kinin variant has obvious advantages, such as the half-life is further prolonged while the affinity activity with receptor is maintained, and the in vivo efficacy of the PEG-modified kinin variant is superior to that of PEG-modified wild-type kinin, so that the druggability of the kinin is further improved. In addition, the PEG-modified kinin show remarkable efficacy in various administration routes, especially in subcutaneous injection and oral administration, which is convenient in clinical use, and effectively improves the compliance of a patient, and is more suitable for long-term therapeutic administration, such as the convalescent treatment, relapse prevention and the like of a patient with cerebral stroke.
Owner:ZONHON BIOPHARMA INST

Inhibitor of kinin KIF18A and application thereof

PendingCN121693499AOrganic active ingredientsOrganic chemistryDiseaseCell Proliferation Process
The invention provides a KIF18 inhibitor and a synthesis method thereof, and particularly provides a compound shown as a formula (I), and the compound can regulate KIF18A protein, so that the cell cycle and the cell proliferation process are influenced to treat cancers and cancer-related diseases. Also provided are pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.
Owner:SHANGHAI APEIRON THERAPEUTICS CO LTD

Therapeutic agents and uses thereof

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
Owner:JANSSEN BIOTECH INC

Human plasma kallikrein inhibitor

The present invention discloses compounds of formula I and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. The present invention also provides pharmaceutical compositions comprising at least one compound of the present invention, and methods of using the compounds and compositions of the present invention to treat and prevent diseases and conditions characterized by undesirable plasma kallikrein activity.
Owner:BIOCRYST PHARMACEUTICALS INC